What question did this study set out to answer?

The study aims to assess the effectiveness of pulse steroid therapy in patients with severe ARDS requiring veno-venous ECMO.

ID:35 FC-D05-4 Pulse Steroid Therapy for Severe Acute Respiratory Distress Syndrome: Propensity Score-matched Analysis

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates pulse steroid therapy impact on mortality in severe ARDS patients using ECMO, suggesting no benefit.

The study aims to assess the effectiveness of pulse steroid therapy in patients with severe ARDS requiring veno-venous ECMO.
Patient data sourced from the J-CARVE registry across 24 hospitals in Japan between January 2012 and December 2022.
373 patients were treated with corticosteroids and divided into pulse and non-pulse therapy groups, with propensity score matching applied.
Outcomes compared include all-cause hospital mortality and ECMO-free days within 28 days.
All-cause hospital mortality was 41.7% in the pulse steroid group and 47.9% in the non-pulse group (odds ratio, 1.28; 95% CI: 0.53–3.12, p = 0.68).
Median ECMO-free days were 9.5 days in the pulse group vs. 3 days in the non-pulse group (p = 0.69).

Kawano et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark